C: Use with caution if Advantages outweigh risks. Animal reports clearly show risk and human scientific studies not out there or neither animal nor human reports carried out.
pentobarbital will lessen the level or impact of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lonafarnib is often a sensitive CYP3A4 substrate. Coadministration with solid or average CYP3A4 inducers is contraindicated.
pentobarbital raises toxicity of ifosfamide by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of. CYP3A4 inducers may raise the metabolism of ifosfamide to its active alkylating metabolites.
pentobarbital will minimize the extent or impact of carvedilol by influencing hepatic enzyme CYP2C9/ten metabolism. Use Warning/Observe.
CYP3A4 inducers could raise the development from the neurotoxic/nephrotoxic ifosfamide metabolite, chloroacetaldehyde. Closely check sufferers having ifosfamide with CYP3A4 inducers for toxicities and take into account dose adjustment.
pentobarbital will minimize the level or effect of triamcinolone acetonide injectable suspension by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.
With therapeutic doses of TCAs, barbiturates increase metabolism and reduce blood concentrations of TCAs.
pentobarbital will decrease the extent or outcome of methylprednisolone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.
pentobarbital will lower the extent or result of ritonavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.
This drug may well interfere with the absorption of orally administered griseofulvin, decreasing its blood ranges; effects of blood amount reduction not known; preferable to stay away from concomitant administration of these drugs
Watch Carefully (one)pentobarbital will lessen the extent or result of fentanyl intranasal by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep check here an eye on Intently. Coadministration of fentanyl with CYP3A4 inducers may lead to your decrease in fentanyl plasma concentrations, deficiency of efficacy or, quite possibly, advancement of a withdrawal syndrome within a patient who's got created physical dependence to fentanyl. Immediately after halting a CYP3A4 inducer, as the effects from the inducer decline, the fentanyl plasma focus will improve which could increase or prolong the two the therapeutic and adverse effects.
pentobarbital will minimize the extent or influence of rabeprazole by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Importance Unknown.
pentobarbital will decrease the extent or outcome of fedratinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Impact of coadministering a powerful CYP3A4 inducer with fedratinib hasn't been researched.
fentanyl iontophoretic transdermal technique and pentobarbital each improve sedation. Stay away from or Use Alternate Drug. Limit use to clients for whom alternate treatment method options are insufficient